How Visible Is Your Clinical Trial To AI?

By Ross Jackson, Ross Jackson Consulting

For years, clinical trial visibility has largely been treated as a search, registry, outreach, or recruitment problem. Is the trial listed on ClinicalTrials.gov? Is there a recruitment page? Are sites activated? Are physicians aware? Are ads running?

Those questions still matter, but they no longer capture the full picture. As patients, physicians, site teams, and operations leaders begin using AI tools to interpret clinical trial information, sponsors face a newer question: When AI tools summarize, compare, and explain your trial, do they make the right stakeholder more likely to trust it, shortlist it, refer into it, or act upon it?

That is different from traditional visibility. It isn’t simply, “Can the trial be found online?” It is, “When the available information is interpreted by AI, does the resulting answer help or hinder the decision the stakeholder is trying to make?”

AI Is Becoming An Interpretation Layer

AI tools are no longer functioning only as novelty chatbots or writing aids. For many users, they are becoming a first-pass interpretation layer.

A patient may ask whether trials exist for their condition. A physician may ask what investigational options are available. A PI may try to understand a sponsor’s asset. A site director may gauge operational feasibility. A sponsor or CRO may compare sites, vendors, or partners.

In each case, AI is not just returning links. It is summarizing, prioritizing, and comparing. That creates a new form of recruitment and operational risk.

A trial can be technically visible and still be poorly interpreted, mentioned but not explained, findable but not compelling, scientifically accurate but silent on the practical questions that matter to the person interrogating their favorite AI chat bot. For patient recruitment, site engagement, and referral generation, that distinction matters.

Being Online Is Not The Same As Being AI-Ready

Most sponsors already have trial information online somewhere — a registry entry, pipeline page, press release, scientific poster, investor presentation, or recruitment page. The problem is that AI tools do not necessarily interpret that information the way the sponsor assumes.

A registry listing may be accurate but difficult for a patient to understand. A pipeline page may explain the asset but not the participant pathway. A press release may be written for investors, not physicians or patients. A recruitment page may invite inquiries but offer little reassurance about what participation involves.

The issue is not that AI cannot read this material. Increasingly, AI systems can interpret PDFs, webpages, transcripts, images, and other forms of content. The issue is whether the most important information is easy to retrieve, trust, cite, compare, and convert into a useful decision pathway.

A PDF poster or investor presentation may contain valuable information, but that doesn’t mean it is the best primary source for AI-mediated discovery. Sponsors should not assume that because information exists somewhere, AI tools will find it, prioritize it correctly, interpret it in context, and present it in a form that helps the intended stakeholder.

What An AI Visibility Audit Should Test

An AI visibility audit should not simply ask whether ChatGPT can find a trial. A useful audit should test how different AI tools interpret the trial across stakeholder perspectives, decision contexts, and stages of the information journey.

At a minimum, sponsors should understand whether AI-generated answers can:

• find the trial or sponsor
• explain the trial accurately
• identify the relevant patient population
• distinguish it from competing or adjacent studies
• explain eligibility and burden clearly
• identify credible sources
• avoid overstating or understating the evidence
• provide a sensible route for further action
• make the trial more likely to be trusted, shortlisted, referred into, or inquired about.

Traditional SEO-style thinking is too narrow here. The goal is not simply to appear in an answer but to understand how that answer will affect stakeholder confidence and behavior.

In one of my recent audits, the AI tools used identified the relevant sponsor and asset, but several answers stopped at a broad scientific summary. They did not clearly explain the patient pathway, the practical implications for sites, or what a physician or patient should do with the information. That is the difference between being visible and being actionable.

Mentions, Citations, And Actionability Are Different Signals

One useful distinction in this regard is between mentions, citations, and actionability.

A mention means the AI recognizes the trial, sponsor, or asset. A citation, where available, suggests it is relying on a particular source as evidence. Actionability is different again. It asks whether the answer helps the stakeholder understand what to do with the information.

Those signals should not be confused.

A trial may be mentioned but not presented as credible or relevant. A sponsor may be recognized but not cited as the primary source. A study may be described accurately with no clear path for a patient, physician, site, or referrer to act.

In practice, actionability may be the most important signal for recruitment. If a patient still doesn’t know whether the trial is relevant, where it is available, or who to contact, visibility has not translated into recruitment value.

Test By Stakeholder Persona, Not Generic Prompt

A common mistake is asking generic questions such as, “What is Trial X?,” which can be a useful starting point but is not enough.

Clinical trial decisions are stakeholder-specific. A patient, physician, PI, and site coordinator are not asking the same questions, even when they are looking at the same trial.

A patient wants to know whether the trial is relevant to someone like them and what participation involves. A physician wants to know which patients might be suitable and how to discuss it with them or refer them into the study. A PI wants to know whether the design is sound, whether the asset is scientifically interesting, and whether the trial is worth the site’s reputation and effort.

A site director wants to know how burdensome the study is, whether recruitment is realistic, and whether the sponsor or CRO appears organized. A sponsor or CRO may want to know which sites, vendors, or partners look credible and easy to evaluate.

The same AI answer can be factually acceptable and still fail the user it is meant to help. That is why audits should test realistic decision contexts not just brand or trial-name recognition.

Test Across Multiple AI Platforms

Sponsors should also avoid the assumption that one AI platform represents the whole environment.

ChatGPT, Claude, Gemini, Perplexity, Copilot, and Google AI Overviews will use different retrieval behaviors, source ecosystems, citation practices, and levels of caution. And they won’t interpret the same trial identically.

One tool may give a confident summary while another hedges. One may cite a registry entry while another leans on a press release or third-party source. One may compare the trial with competitors while another avoids recommendation-like language when the prompt comes close to medical advice or investigational treatment selection.

This variation is a practical risk not a technical curiosity. If patients, physicians, sites, or partners are using different AI tools, sponsors need to know whether the trial is presented consistently across that environment.

Review The Source Ecosystem

An audit should not stop at the AI output. The more important question is often why the tool answered that way.

Did the AI rely on the sponsor’s own site? The trial registry? A press release? A third-party summary? A patient advocacy page? An academic article? An outdated news story?

Was key information missing from accessible web content? Was useful information buried in PDFs, slide decks, or investor materials? Were the pages current, easy to navigate, and clearly connected to the user’s decision?

This matters because a sponsor’s real competition for AI attention may not be another sponsor. It may be a journal article, disease education page, advocacy site, hospital page, registry listing, or old media report.

AI tools draw from whichever sources are easiest to retrieve, interpret, and summarize. Sponsors therefore need to ask not only whether they have information online, but whether they have the right information in the right form. That does not mean abandoning PDFs, posters, videos, or slide decks. It means connecting those assets to clearer, current, consistent, structured web content that explains what matters to each audience.

Score The Right Things

A single visibility score is unlikely to be enough.

A practical audit should separate dimensions, such as discoverability, interpretation quality, source confidence, stakeholder relevance, competitive clarity, burden clarity, next-step clarity, and shortlisting or inquiry likelihood. This last category is especially important.

A trial may score well on basic discoverability but poorly on actionability. It may be visible to AI but not yet ready for AI-mediated recruitment, referral, or site engagement. The most useful findings are rarely obvious factual errors. Quite often, the problem is subtler.

AI tools may get the trial broadly right but fail to explain why it matters. They may describe the mechanism but not the patient pathway. They may compare studies but miss the differentiators that matter to sites or physicians. They may rely on technically valid sources that do not provide the most useful explanation for the stakeholder. AI visibility, in other words, is not only a search problem but also a communication, recruitment, and operational readiness problem.

The Aim Is Not To Game AI

Sponsors should not approach this as keyword manipulation.

The aim is not to trick AI tools into recommending a trial. In clinical research, that would be inappropriate and potentially dangerous. The aim is to make accurate, balanced, current, consistent, and useful information easier for AI systems to retrieve and explain.

That means improving the quality of the source material — registry information, sponsor pages, patient summaries, physician FAQs, site-facing materials, disease education content, publications, transcripts, and clear contact pathways. It also means recognizing that different stakeholders need different explanation layers. Patients need clarity and reassurance. Physicians need referral relevance and scientific credibility. Sites need operational context. Sponsors and CROs need evidence of capability and fit. If those layers do not exist, AI will attempt to fill the gaps using whatever material is available.

A Practical Starting Point

Sponsors do not need a perfect audit process to start learning from this. A basic approach is to test a small number of prompts across several AI tools using realistic stakeholder scenarios, then ask:

• What did the AI surface?
• What did it miss?
• Which sources did it rely on?
• Was the answer accurate, clear, and balanced?
• Did it address the user’s real decision?
• Did it explain a credible route forward?
• Would this answer increase or reduce the likelihood of action?

The output itself is not the key to understanding AI visibility; the interpretation is the key. That interpretation requires clinical trial judgment, recruitment understanding, stakeholder awareness, and knowledge of the competitive landscape.

Conclusion

AI visibility is not a replacement for trial registries, recruitment strategy, site engagement, or physician outreach. But it is becoming part of the information environment in which those activities take place.

Sponsors should begin auditing how AI tools interpret their trials before those interpretations start influencing patient inquiries, physician referrals, site engagement, and/or partner selection in ways they have not anticipated.

So, the question is no longer simply, “Is our trial information online?” It is, “When AI interprets our trial information, does the answer help the right stakeholder take the right next step?”

Once sponsors can see where AI interpretation is helping or hindering stakeholder action, the next question is what to fix — and how to prioritize those fixes before they affect recruitment. Learn more about those fixes in part two of this series.

About The Author:

Ross Jackson is a patient recruitment specialist and author of the books The Patient Recruitment Conundrum and Patient Recruitment for Clinical Trials using Facebook Ads.

Having started out with digital marketing in 1998, Ross quickly developed a specialty in the healthcare niche, evolving into a focus on clinical trials and the problems of patient recruitment and retention.

Over the years Ross branched out from the purely digital and now operates in an advisory capacity helping sponsors, CROs, sites, solutions providers, and others in the industry to improve their patient recruitment and retention capabilities — having advised and consulted on over 100 successful projects.